Gene therapy and nasopharyngeal carcinoma | Zendy

J. Hughes | Zendy; Ghassan Alusi | Zendy; Yiting Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gene therapy and nasopharyngeal carcinoma

Author(s) -

J. Hughes,

Ghassan Alusi,

Yiting Wang

Publication year - 2012

Publication title -

rhinology journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.275

H-Index - 57

eISSN - 1996-8604

pISSN - 0300-0729

DOI - 10.4193/rhino11.239

Subject(s) - medicine , nasopharyngeal carcinoma , genetic enhancement , oncology , head and neck cancer , chemotherapy , radiation therapy , gene , intensive care medicine , genetics , biology

In 2003, a non-replicating adenoviral gene therapy product received the world`s first government licence for the treatment of head and neck cancer. Two years later approval was granted to a replication-selective adenovirus for the treatment of nasopharyngeal carcinoma in combination with chemotherapy. This review introduces the reader to gene therapy as an emerging treatment modality, and outlines its application to the management of nasopharyngeal carcinoma by examining recent pre-clinical and clinical research.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research